

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	10/528,346
Filing Date	March 16, 2005
First Named Inventor	Sawa, Yoshiki, et. al.
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	082368-003400US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/TCG/	AA	EP	0 824 918	A1	02-25-1998	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>

Examiner
Signature

/Terra Cotta Gibbs/

Date
Considered

12/11/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	10/528,346
Filing Date	March 16, 2005
First Named Inventor	Sawa, Yoshiki, et. al.
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	082368-003400US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AB	BREUSS, J. M. et al.; "Activation of nuclear factor- κ B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model"; <u>Circulation</u> ; 2002; pp. 633-638; Vol. 105	
	AC	FEELY, B.T. et al.; "Nuclear factor-kappaB transcription factor decoy treatment inhibits graft coronary artery disease after cardiac transplantation in rodents"; <u>Transplantation</u> ; December 15, 2000; pp. 1560-1568; Vol. 70, No. 11	
	AD	HUYNH, Tam T. T. et al.; "Control of intimal hyperplasia by local modulation of NF- κ B activity in experimental vein grafts"; <u>Surgical Forum</u> ; 1997; pp. 441-444; Vol. 48	
	AE	MANN, M.J. et al.; "Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial"; <u>Lancet</u> ; October 30, 1999; pp. 1493-1498; Vol. 354, No. 9189	
	AF	MORISHITA, Ryuichi et al.; "A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation <i>in vivo</i> "; <u>Proc. Natl. Acad. Sci. U.S.A.</u> ; June 1995; pp. 5855-5859; Vol. 92	
	AG	SHINTANI, T. et al.; <u>Journal of Japan Surgical Society</u> ; April 13, 2002; Abstract No. SF0432, pp. 237	✓
	AH	SHINTANI, T. et al.; "Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia"; <u>Ann. Thorac. Surg.</u> October 2002; pp. 1132-1137, discussion 1137-1138; Vol. 74, No. 4	
	AI	YOSHIMURA, S. et al.; "Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy"; <u>Gene Ther.</u> ; November 2001; pp. 1635-1642; Vol. 8, No. 21	

Examiner
Signature

/Terra Cotta Gibbs/

Date
Considered

12/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60665986 v1